Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-69.68M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 37.50 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.90 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 7.27% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | 4.70% |
| Return on Assets (Trailing 12 Months) | 3.47% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.98 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.06 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 56.86M |
| Free Float | 53.47M |
| Market Capitalization | $127.94M |
| Average Volume (Last 20 Days) | 1.18M |
| Beta (Past 60 Months) | 2.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.97% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.47% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |